These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 28199076)

  • 1. The effect of extended release tolterodine used for overactive bladder treatment on female sexual function.
    Zachariou A; Filiponi M
    Int Braz J Urol; 2017; 43(4):713-720. PubMed ID: 28199076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolterodine immediate release improves sexual function in women with overactive bladder.
    Hajebrahimi S; Azaripour A; Sadeghi-Bazargani H
    J Sex Med; 2008 Dec; 5(12):2880-5. PubMed ID: 18785896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).
    Herschorn S; Staskin D; Tu LM; Fialkov J; Walsh T; Gooch K; Schermer CR
    Health Qual Life Outcomes; 2018 Apr; 16(1):69. PubMed ID: 29673355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study).
    Staskin D; Herschorn S; Fialkov J; Tu LM; Walsh T; Schermer CR
    Int Urogynecol J; 2018 Feb; 29(2):273-283. PubMed ID: 28620791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparisons of the Clinical Outcomes and Urodynamic Effects of Mirabegron versus Tolterodine Treatment for Female Overactive Bladder Syndrome: A Subgroup Analysis of a Controlled, Randomised, Prospective Study.
    Hsiao SM; Chang TC; Chen CH; Wu WY; Lin HH
    Low Urin Tract Symptoms; 2018 Sep; 10(3):215-220. PubMed ID: 28436145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective randomized trial comparing the use of tolterodine or weighted vaginal cones in women with overactive bladder syndrome.
    Yüce T; Dökmeci F; Çetinkaya ŞE
    Eur J Obstet Gynecol Reprod Biol; 2016 Feb; 197():91-7. PubMed ID: 26720597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Percutaneous tibial nerve stimulation versus tolterodine for overactive bladder in women: a randomised controlled trial.
    Preyer O; Umek W; Laml T; Bjelic-Radisic V; Gabriel B; Mittlboeck M; Hanzal E
    Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():51-6. PubMed ID: 26073262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Tolterodine and Vaginal Estradiol Cream for Overactive Bladder Symptoms After Randomized Single-Therapy Treatment.
    Ellington DR; Szychowski JM; Malek JM; Gerten KA; Burgio KL; Richter HE
    Female Pelvic Med Reconstr Surg; 2016; 22(4):254-60. PubMed ID: 26945271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
    Kuo HC; Lee KS; Na Y; Sood R; Nakaji S; Kubota Y; Kuroishi K
    Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, open-label, tolterodine-controlled, comparative study of the novel antimuscarinic agent imidafenacin in patients with overactive bladder.
    Pushkar DY; Kasyan GR; Kolontarev KB; Sharvadze GG; Mukhametshina EI
    Neurourol Urodyn; 2019 Jun; 38(5):1313-1321. PubMed ID: 30888691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolterodine ER reduced increased bladder wall thickness in women with overactive bladder. A randomized, placebo-controlled, double-blind, parallel group study.
    Bray R; Cartwright R; Cardozo L; Hill S; Guan Z; Khullar V
    Neurourol Urodyn; 2018 Jan; 37(1):237-243. PubMed ID: 28407338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does the Severity of Overactive Bladder Symptoms Correlate With Risk for Female Sexual Dysfunction?
    Juliato CRT; Melotti IGR; Junior LCS; Britto LGO; Riccetto CLZ
    J Sex Med; 2017 Jul; 14(7):904-909. PubMed ID: 28622875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of overactive bladder syndrome on female sexual function.
    Lin XD; Lin N; Ke ZB; Xu N; Jiang P; Li H
    Medicine (Baltimore); 2021 May; 100(20):e25761. PubMed ID: 34011037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan.
    D'Souza AO; Smith MJ; Miller LA; Doyle J; Ariely R
    J Manag Care Pharm; 2008 Apr; 14(3):291-301. PubMed ID: 18439051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of a randomized, double-blind, active-controlled clinical trial with propiverine extended release 30 mg in patients with overactive bladder.
    Leng J; Liao L; Wan B; Du C; Li W; Xie K; Shen Z; Xu Z; Wu S; Fang Z; Ma L; Han S; Feustel C; Yang Y; Madersbacher H
    BJU Int; 2017 Jan; 119(1):148-157. PubMed ID: 27087507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Impact of overactive bladder on sexual function in women].
    Del Rosso A; Pace G; Di Pierro ED; Masciovecchio S; Galatioto GP; Vicentini C
    Urologia; 2011; 78(3):200-2. PubMed ID: 21786235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symptom score change and patient versus doctor satisfaction in overactive bladder before and after anti-muscarinic treatment.
    Bunyavejchevin S
    J Obstet Gynaecol Res; 2015 Jun; 41(6):957-61. PubMed ID: 25773663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.